Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
132 hedge funds and large institutions have $495M invested in Kezar Life Sciences in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 60 increasing their positions, 31 reducing their positions, and 20 closing their positions.
409% more call options, than puts
Call options by funds: $9.9M | Put options by funds: $1.95M
94% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 31
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
9% more capital invested
Capital invested by funds: $454M → $495M (+$41.5M)
4% more funds holding
Funds holding: 127 → 132 (+5)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6.71% less ownership
Funds ownership: 90.88% → 84.17% (-6.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$27.2M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$13.3M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$9.19M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$7.78M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$5.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$12.1M |
| 3 |
DM
Deerfield Management
New York
|
-$11.7M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$11M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.92M |
KZR Hedge Fund Activity: Q3 2022 in Review
132 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q3 2022, worth a combined $495M — up 9.1% from $454M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KZR positions and 20 closed out — a net gain of 5 holders — while 60 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $27.2M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $13.3M sold.
- 132 institutional investors held Kezar Life Sciences (KZR) as of Q3 2022, up from 127 in Q2 2022.
- Funds reported $495M of Kezar Life Sciences stock for Q3 2022, up 9.1% quarter-over-quarter.
- 25 funds opened new Kezar Life Sciences positions in Q3 2022 and 20 closed out, a net change of +5 holders.
- The largest Kezar Life Sciences buyer in Q3 2022 was State Street, an estimated $27.2M added.
- The largest Kezar Life Sciences seller in Q3 2022 was Point72 Asset Management, an estimated $13.3M sold.
Based on aggregated 13F filings for Q3 2022.